Skip to main content
. Author manuscript; available in PMC: 2023 Oct 5.
Published in final edited form as: Neuron. 2022 Aug 11;110(19):3106–3120.e7. doi: 10.1016/j.neuron.2022.07.015

Figure 6. Inhibition of ALK receptors reduces vascular leakage and blocks the progression of MS.

Figure 6.

(A) Clinical scores in mice treated daily with intraperitoneal injections of LDN193189 and SB431542 (LDN+SB) starting at day 1 post-MOG immunization. Results shown in panels A and B are a composite of two independent rounds of experiments.

(B) LDN+SB improves body weight recovery in mice shown in panel A.

(C) Representative spinal cord sections. Left panels show that meningeal and parenchymal inflammation (arrows) in spinal cord from DMSO+H2O-treated mice is absent in the LDN+SB-treated mice, 200x H&E. Middle panels show H&E stain, 100x. Right panels show convergent foci of demyelinated white matter (outlined) of spinal cord from DMSO+H2O-treated mice. Normal myelination of LDN+SB-treated mice. LFB stain, 100x.

(D, E) Phosphorylated SMAD1/5 and the EndoMT markers were assessed in the spinal cord microvessels of EAE mice at day 28 post-immunization. Two-tailed ratio paired t tests.

(F, G) Vascular permeability was measured in spinal cords by the Evans blue assay at day 14 post-immunization.

*p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001. All error bars represent the SEM. Individual symbols shown in the graphs in panels E and G represent a single mouse (n=3–6).

See also Figure S10.